News

The Manila Times1h
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
Purple Biotech Ltd. ('Purple Biotech' or 'the Company') (NASDAQ/TASE: PPBT), a clinical-stage company developing ...
Investor's Business Daily on MSN16h
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...